MA50358A - Sémaglutide en thérapie médicale - Google Patents

Sémaglutide en thérapie médicale

Info

Publication number
MA50358A
MA50358A MA050358A MA50358A MA50358A MA 50358 A MA50358 A MA 50358A MA 050358 A MA050358 A MA 050358A MA 50358 A MA50358 A MA 50358A MA 50358 A MA50358 A MA 50358A
Authority
MA
Morocco
Prior art keywords
semaglutide
medical therapy
therapy
medical
Prior art date
Application number
MA050358A
Other languages
English (en)
Inventor
Thomas Hansen
Maria Kabisch
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60083831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50358(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA50358A publication Critical patent/MA50358A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA050358A 2017-10-12 2018-10-10 Sémaglutide en thérapie médicale MA50358A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17196254 2017-10-12

Publications (1)

Publication Number Publication Date
MA50358A true MA50358A (fr) 2020-08-19

Family

ID=60083831

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050358A MA50358A (fr) 2017-10-12 2018-10-10 Sémaglutide en thérapie médicale

Country Status (18)

Country Link
US (4) US12029779B2 (fr)
EP (1) EP3694538A1 (fr)
JP (2) JP7148605B2 (fr)
KR (1) KR20200069316A (fr)
CN (4) CN111212657A (fr)
AU (2) AU2018348929B2 (fr)
BR (1) BR112020006246A2 (fr)
CA (1) CA3078652A1 (fr)
CL (1) CL2020000812A1 (fr)
IL (3) IL322969A (fr)
MA (1) MA50358A (fr)
MX (3) MX2020003049A (fr)
MY (1) MY204827A (fr)
PH (1) PH12020550185A1 (fr)
SG (1) SG11202002841PA (fr)
TW (1) TWI842681B (fr)
WO (1) WO2019072941A1 (fr)
ZA (3) ZA202503387B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322969A (en) * 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2022212271A1 (fr) * 2021-03-29 2022-10-06 Sanford Health Procédés et compositions pour le traitement de troubles du stockage lysosomal
CN119317635A (zh) * 2022-06-08 2025-01-14 载度思生命科学有限公司 用于2型糖尿病和体重管理的可重复使用的多剂量可变剂量的单一笔式注射器
WO2024249659A2 (fr) * 2023-05-30 2024-12-05 The Medical College Of Wisconsin, Inc. Méthodes pour une perte de poids et/ou pour une réduction de gain de poids
US20240404673A1 (en) * 2023-06-05 2024-12-05 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1412384B1 (fr) 2001-06-28 2007-12-26 Novo Nordisk A/S Formulation stable de glp-1 modifie
CA2539253A1 (fr) 2003-09-19 2005-03-31 Novo Nordisk A/S Nouveaux derives de glp-1
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
CN106137952B (zh) 2004-11-12 2020-11-17 诺和诺德公司 促胰岛素肽的稳定制剂
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
KR20150042304A (ko) 2006-04-14 2015-04-20 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
EP2481410B1 (fr) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Dérivés du catéchol comme inhibiteurs de la COMT administrés avec une posologie spécifique
US20100047762A1 (en) 2007-03-20 2010-02-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
PL2373681T3 (pl) 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
CN104327182B (zh) 2009-12-16 2020-04-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
KR101927068B1 (ko) * 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2012016419A1 (fr) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Dérivés de glp-1 et leurs utilisations
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
SG191252A1 (en) 2010-12-22 2013-07-31 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (fr) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprenant des protéines de fusion ou des conjugués ayant une demi-vie améliorée
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
CN103906528A (zh) 2011-06-24 2014-07-02 安米林药品有限责任公司 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
LT2753313T (lt) 2011-09-08 2017-02-10 Mereo Biopharma 2 Limited Farmacinės kompozicijos, apimančios aromatazės inhibitorių
JP6250034B2 (ja) * 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
EP3815684B1 (fr) 2012-06-29 2024-09-04 Amarin Pharmaceuticals Ireland Limited Procédés de réduction du risque d'un événement cardiovasculaire chez un sujet soumis à un traitement par une statine
HRP20251088T1 (hr) * 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
SMT201800492T1 (it) * 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
SG11201805255TA (en) 2015-12-23 2018-07-30 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
EP3648762A4 (fr) 2017-08-04 2021-03-24 Ovid Therapeutics, Inc. Utilisation de gaboxadol dans le traitement du diabète et d'états apparentés
IL322969A (en) * 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy

Also Published As

Publication number Publication date
ZA202503387B (en) 2025-09-25
PH12020550185A1 (en) 2021-03-01
MX2025002188A (es) 2025-04-02
AU2018348929B2 (en) 2025-02-27
RU2020114960A (ru) 2021-10-28
IL273470A (en) 2020-05-31
IL322969A (en) 2025-10-01
US12029779B2 (en) 2024-07-09
JP2020536854A (ja) 2020-12-17
MY204827A (en) 2024-09-18
ZA202503388B (en) 2025-09-25
ZA202503350B (en) 2025-09-25
MX2025002189A (es) 2025-04-02
IL322968A (en) 2025-10-01
JP7475398B2 (ja) 2024-04-26
TW201914611A (zh) 2019-04-16
US20240415935A1 (en) 2024-12-19
SG11202002841PA (en) 2020-04-29
CA3078652A1 (fr) 2019-04-18
US20200237876A1 (en) 2020-07-30
US20250235511A1 (en) 2025-07-24
US12295988B2 (en) 2025-05-13
AU2025203535A1 (en) 2025-06-05
CL2020000812A1 (es) 2020-08-14
BR112020006246A2 (pt) 2021-03-30
CN120241968A (zh) 2025-07-04
AU2018348929A1 (en) 2020-05-07
US12551536B2 (en) 2026-02-17
CN119950682A (zh) 2025-05-09
EP3694538A1 (fr) 2020-08-19
WO2019072941A1 (fr) 2019-04-18
TWI842681B (zh) 2024-05-21
JP2022132414A (ja) 2022-09-08
RU2020114960A3 (fr) 2022-02-11
CN111212657A (zh) 2020-05-29
KR20200069316A (ko) 2020-06-16
US20240316159A1 (en) 2024-09-26
CN119838000A (zh) 2025-04-18
MX2020003049A (es) 2020-07-27
JP7148605B2 (ja) 2022-10-05

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
PL3303632T3 (pl) Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
EP3709882A4 (fr) Attelles diagnostiques et thérapeutiques
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
EP3335740C0 (fr) Hydrogel médical
DK3474802T3 (da) Medicinsk forbinding
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
BR112017002074A2 (pt) vestuário e método de compressão médica terapêutica
MA50358A (fr) Sémaglutide en thérapie médicale
HUE049479T2 (hu) Hidrofil orvostechnikai eszköz
DK3373874T4 (da) Medicinsk forbinding
EP3723692A4 (fr) Déambulateur médical
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
DK3432970T3 (da) In vivo lægemiddelleveringsindretninger
EP3445431A4 (fr) Interface de patient et aspects associés
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
IL250692B (en) Medical treatments based on anamorelin
SI3268374T1 (sl) KV1.3 inhibitorji in njihova medicinska uporaba
HUE054998T2 (hu) Kombinációs terápiák emlõrák kezelésében való alkalmazásra
IL264407A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
PL2988750T5 (pl) Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii
DK3325027T3 (da) Medicinsk implantat
ITUA20163417A1 (it) Fat and medical uses thereof
HUE058645T2 (hu) Gyógyszer köszvény kezelésében való felhasználásra